Given that the prevalence of pathogenic BRCA1 mutations varies between 24% and 41% [26,30], this suggests that potentially up to 70% of ovarian cancer cases might be anticipated and avoided at an early stage. This evidence concerns the gene BRCA1 and ovarian carcinoma.